• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 30th May 2017

Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions

Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers and HTA bodies. Antimicrobial resistance (AMR) occurs when microorganisms such as bacteria, viruses, fungi…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers and HTA bodies.

Antimicrobial resistance (AMR) occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that render the medications used to cure the infections they cause ineffective.

Without new antibiotics, more patients will die from previously treatable infections.

However, a key issue is how antibiotics can be appropriately assessed, particularly by payers and/or health technology assessment (HTA) bodies, to take account of AMR and reflect the full benefit they provide to patients and society.

There are several reasons why we need additional elements of value for antibiotics

  1. AMR is a public health priority. The rise of AMR is recognised as a serious global and urgent threat, and tackling this threat is a priority for leading national and international organisations. Current HTA methods, in general, do not explicitly account for the value of reducing this public health threat, for example of the “insurance” value of having a treatment available in case of a future major or rapidly escalating problem of resistance.
  2. A diverse set of non-inferior antibiotics are valuable to society. Because of the rise of AMR, there is value in developing a new antibiotic for MDR pathogens, even if it is no more effective than existing antibiotics in treating susceptible (non-resistant) pathogens, since it enables diverse prescribing patterns. This concept is unique to antibiotics and is not explicitly considered by HTA bodies.
  3. Non-clinical and microbiology data are important for demonstrating the value of antibiotics. For antibiotics, non-clinical and microbiology data can be important predictors of outcomes. Difficulties in conducting clinical trials for antibiotics for MDR pathogens has led regulators to accept these alternative types of evidence as part of the approval process in areas of high unmet need
  4. Antibiotics have benefits that go beyond the patient treated. When one patient is treated with an antibiotic, this reduces the spread of the infectious disease, leading to population-wide benefits.
  5. Antibiotics enable other types of treatment and procedures. As well as treating infections, antibiotics reduce the risk associated with other types of treatment such as surgery and chemotherapy.

A new Briefing, authored by OHE’s Professor Adrian Towse and colleagues together with Professor Robert Masterton and Peter West from The Academy of Infection Management (AIM), discusses 10 elements of value which can be split into two groups: four relevant benefits typically included in HTA, and six other types of benefits not traditionally included. These were discussed at a multi-country, multi-disciplinary, multi-stakeholder Value Forum.

Overall, there was broad agreement at the Forum that these additional elements of value were potentially relevant for HTA of new antibiotics. Participants offered a number of valuable insights into how further work could be approached in order to maximise both its practicality and its potential policy impact. These are summarised in the Briefing.

The Forum and the report result from a joint collaboration between OHE and AIM, who brought together leading experts from HTA bodies, payer organisations, industry and regulatory bodies, with economists and clinical experts across Europe to discuss the valuation of antibiotics. 

Access the briefing here.

A two page summary of the briefing, written by Dr Chris Henshall and Professor Adrian Towse is available here.

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation
  • Briefing

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • June 2020

OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare

Read more
  • News
  • May 2020

Indication-Based Pricing: Are We All Onboard?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!